Two Cases of Myeloproliferative Neoplasm with a Concurrent JAK2V617F Mutation and BCR/ABL Translocation without Chronic Myelogenous Leukemia Phenotype Acquisition during Hydroxyurea Treatment

참고문헌 (20)

1. Tefferi A, "Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms", Leukemia, 22, pp.14~22 (2008)
2. Swerdlow SH, "WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed" (2008), IARC Press
3. Hummel JM, "Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms", Diagn Mol Pathol, 21, pp.176~183 (2012)
4. Véronèse L, "A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2(V617F) myeloproliferative neoplasm", Leuk Res, 34, pp.e94~e96 (2010)
5. Inami M, "Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia", Leukemia, 21, pp.1103~1104 (2007)
6. Campiotti L, "JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia", Leuk Res, 33, pp.e212~e213 (2009)
7. Kim YK, "Simultane ous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders", Leuk Res, 32, pp.993~995 (2008)
8. Bee PC, "A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders", Int J Hematol, 91, pp.136~139 (2010)
9. Bocchia M, "Insights into JAK2-V617F mutation in CML", Lancet Oncol, 8, pp.864~866 (2007)
10. Jallades L, "Emergence of therapy-unrelated CML on a background of BCR-ABLnegative JAK2V617F-positive chronic idiopathic myelofibrosis", Leuk Res, 32, pp.1608~1610 (2008)
11. Scott LM, "The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders", Blood, 106, pp.2920~2921 (2005)
12. Mirza I, "Transformation of polycythemia vera to chronic myelogenous leukemia", Arch Pathol Lab Med, 131, pp.1719~1724 (2007)
13. Conchon MR, "Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia", Int J Hematol, 88, pp.243~245 (2008)
14. Mizutani S, "Emergence of chronic myelogenous leukemia during treatment for essential thrombocythemia", Int J Hematol, 91, pp.516~521 (2010)
15. Xiao X, "Coexistence of JAK2V617F mutation and BCR-ABL1 transcript in two Chinese patients with chronic myelogenous leukemia", Acta Haematol, 127, pp.47~49 (2012)
16. Hussein K, "Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation", Blood, 109, pp.4106~4107 (2007)
17. Bornhäuser M, "Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis", Leukemia, 21, pp.1824~1826 (2007)
18. Krämer A, "JAK2-V617F and BCR-ABL--double jeopardy?", Leuk Res, 32, pp.1489~1490 (2008)
19. Cambier N, "JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders", Leukemia, 22, pp.1454~1455 (2008)
20. Gattenlohner S, "BCR-ABL positive chronic myeloid leukemia with concurrent JAK2 (V617F) positive myelodysplastic syndrome", myeloproliferative neoplasm (RARS-T), 2009, pp.84, 306~307

관련 논문AI추천